Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Universite Catholique de Louvain |
| Country | Belgium |
| Start Date | Jan 01, 2023 |
| End Date | Sep 30, 2027 |
| Duration | 1,733 days |
| Number of Grantees | 19 |
| Roles | Associated Partner; Participant; Coordinator |
| Data Source | European Commission |
| Grant ID | 101072632 |
Antimicrobial resistance, which is caused by multi-drug-resistant bacterial pathogens is a global health emergency. Gram-negative bacteria (GNB) notably hinder effective treatment because of their impermeable outer membrane (OM). Consequently, many standard-of-care (SOC) antibiotics cannot access intracellular targets in GNB.
The objective of the BREAKthrough European Training Network (ETN) is to sensitise GNB to these antibiotics by making their OM permeable. To this end, we will develop inhibitors of three protein machineries that are responsible for OM maintenance.
Importantly, many known antibacterial agents have characteristics different from drugs that are directed against targets in mammalian cells.
To define better rules for antibacterial drug development a data hub will be created to assemble information on the physico-chemical characteristics of molecules that can pass the OM.To achieve these goals, a multi-disciplinary academic-industrial consortium has been assembled with organic chemists, computational chemists and specialists in high-throughput drug screening, zebrafish infection models, bacterial morphogenesis and the molecular biology of the three targets.
The expected outcomes of the BREAKthrough ETN include (i) the development of new chemical space rules for drugs that need to cross the OM, (ii) the discovery of new inhibitors that interfere with OM maintenance to overcome the insensitivity of Gram-negative pathogenic bacteria towards SOC antibiotics and (iii) providing 10 Early Stage Researchers with scientific, technical, business and transferable skills to become professional drug developers with a keen eye for the hurdles in the development of these drugs in an industrial context.
Universitat Rovira I Virgili; Fundacio Privada Institut Catala D'Investigacio Quimica; Abac Therapeutics, Sl; The University of Queensland; Stichting Vu; Fundacion Privada Instituto de Salud Global Barcelona; Symeres Netherlands Bv; University of Newcastle Upon Tyne; Universite Catholique de Louvain; F. Hoffmann-la Roche Ag; Stichting Amsterdam Umc; Universitat de Barcelona; Universita Degli Studi Di Milano; Aicuris Anti-Infective Cures Ag; Accelopment Schweiz Ag; Centre National de la Recherche Scientifique CNRS; Syngulon; Univerza V Ljubljani; Naicons Srl
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant